J.P. Morgan Chase & Co.

J.P. Morgan Chase & Co. is out with a research report on SanDisk Corp (NASDAQ: SNDK) and is raising its price target to $68 from $51 but is keeping its Neutral rating on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "SanDisk reported Q3 results that were better than ours...

J.P. Morgan Chase & Co. is out with a research report on UPS (NYSE: UPS) and it has an Overweight rating and a $82 price target on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "While small package demand indicators in 3Q suggest that UPS likely saw y/y declines in volumes...

J.P. Morgan Chase & Co. is out with a research report on Gentex Corporation (NASDAQ: GNTX) and it is lowering its price target to $32 from $33, and it has a Neutral rating on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "GNTX shares sold off 5% on Thursday as an uneventful...

J.P. Morgan Chase & Co. is out with a research report on Goodyear Tire (NYSE: GT) and it has an Overweight rating and a $19 price target on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "On GT, 3Q EPS could land in the $0.40-0.45 range (vs. consensus $0.25, JPM unchanged...

J.P. Morgan Chase & Co. is out with a research report on St. Jude Medical (NYSE: STJ) and it has an Overweight rating and a $55 price target on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "For St. Jude, we are lowering our 4Q sales forecast by $4M to $1.398B (+3.5%), as...

J.P. Morgan Chase & Co. is out with a research report on Harley-Davidson (NYSE: HOG) and is lowering its price target to $38 from $44, and it has a Neutral rating on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "Q3 sloppy on gross margin, but end demand seeing encouraging...

J.P. Morgan Chase & Co. is out with a research report on FXCM (NYSE: FXCM) and it is raising its price target to $19 from $17, and it has an Overweight rating on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "We are removing FXCM from J.P. Morgan's US Analyst Focus List....

J.P. Morgan Chase & Co. is out with a research report on Amgen (NASDAQ: AMGN) and it has an Overweight rating and a $70 price target on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "We have increased our 3Q EPS estimate to $1.31 from $1.30 (cons: $1.29), though we are...

J.P. Morgan Chase & Co. is out with a research report on Research In Motion (NASDAQ: RIMM) and it has a Neutral rating and a $24 price target on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "RIM held a press conference saying they have restored normal service after a...

J.P. Morgan Chase & Co. is out with a research report on RealD Inc. (NYSE: RLD) and is removing it from the Focus List, but is keeping its Overweight rating and a $30 price target on shares. In an note to clients, J.P. Morgan Chase & Co. writes, "There are no changes to our estimates. We...

J.P. Morgan Chase & Co. is out with a research report on ViroPharma Incorporated (NASDAQ: VPHM) and is initiating coverage with an Overweight rating and a $23 price target on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "ViroPharma's value driver is Cinryze, an orphan drug...

J.P. Morgan Chase & Co. is out with a research report on CarMax Inc. (NYSE: KMX) and is lowering its price target to $29 from $34, but is keeping its Neutral rating on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "Following KMX's F2Q conference call, we feel more...

J.P. Morgan Chase & Co. is out with a research report on Regeneron Pharmaceuticals (NASDAQ: REGN) and is initiating coverage with a Neutral rating and a $60 price target on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "Regeneron is a leader in the midcap biotech space with...

J.P. Morgan Chase & Co. is out with a research report on The McGraw-Hill Companies (NYSE: MHP) and is reiterating its Overweight rating and its $46 price target on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "We're reiterating our Overweight rating on McGraw-Hill shares...

J.P. Morgan Chase & Co. is out with a research report on Alexion Pharmaceuticals (NASDAQ: ALXN) and is initiating coverage with an Overweight rating and a $81 price target on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "price target of $81. Alexion has executed one the...